Related Experiment Videos
Bortezomib treatment for multiple myeloma.
Brad L Stanford1, Stacey D Zondor
1School of Pharmacy, Texas Tech Health Sciences Center, Lubbock, TX, USA. brad.stanford@ttuhsc.edu
The Annals of Pharmacotherapy
|November 25, 2003
Summary
Bortezomib shows significant activity in treating relapsed and refractory multiple myeloma (MM). This novel proteasome inhibitor offers a new therapeutic option for MM patients with limited choices.
Area of Science:
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) therapy often yields temporary responses.
- Limited treatment options exist for relapsed and refractory MM.
Purpose of the Study:
- To review the pharmacology and pharmacokinetics of bortezomib.
- To evaluate the role of bortezomib in multiple myeloma therapy.
Main Methods:
- MEDLINE search conducted from 1985 to May 2003.
- Included meeting abstracts, bibliographies, and package inserts.
- Focused on human clinical studies, particularly Phase II trials.
Main Results:
- Bortezomib is a novel anticancer agent.
- Demonstrated significant activity in relapsed and refractory multiple myeloma.
Conclusions:
- Bortezomib represents a novel therapeutic modality for MM.
- Offers a new option for patients with limited treatment alternatives.